1. Home
  2. KZIA
  3. KZIA News

Latest Kazia Therapeutics Limited (KZIA) News on September 3, 2025

Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)
KZIA

Simply Wall St.

3 months ago

Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

KZIA

MT Newswires

3 months ago

Top Midday Gainers

KZIA

MT Newswires

3 months ago

Kazia Therapeutics Says Preclinical Data Show Paxalisib's Potential in Reducing Breast Cancer Symptoms; Shares Jump

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
KZIA

PR Newswire

3 months ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

KZIA

MT Newswires

3 months ago

Kazia Therapeutics Doses First Patient in Phase 1 Trial of Paxalisib for Advanced Breast Cancer

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
KZIA

PR Newswire

3 months ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Highlights Recent Progress and Provides Business Update
KZIA

PR Newswire

4 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
KZIA

PR Newswire

5 months ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
KZIA

PR Newswire

6 months ago

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
KZIA

Insider Monkey

7 months ago

Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?

KZIA

MT Newswires

7 months ago

Sector Update: Health Care Stocks Gain Thursday

KZIA

MT Newswires

7 months ago

Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
KZIA

PR Newswire

7 months ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
KZIA

Insider Monkey

7 months ago

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
KZIA

PR Newswire

8 months ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
KZIA

TipRanks

8 months ago

Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering

KZIA

MT Newswires

8 months ago

Kazia Therapeutics Launches $2 Million Registered Direct Offering

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
KZIA

PR Newswire

8 months ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
KZIA

Benzinga

8 months ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

KZIA

MT Newswires

8 months ago

Update: Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug

KZIA

MT Newswires

8 months ago

Kazia Therapeutics Shares Drop After FDA Derails Fast Track of Potential Brain Cancer Drug

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
KZIA

PR Newswire

8 months ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
KZIA

PR Newswire

9 months ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
KZIA

PR Newswire

10 months ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing
KZIA

TipRanks

a year ago

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
KZIA

PR Newswire

a year ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
KZIA

PR Newswire

a year ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

KZIA

MT Newswires

a year ago

Kazia Therapeutics Executes Deal With QIMR Berghofer Medical to Obtain Intellectual Property License

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
KZIA

PR Newswire

a year ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
KZIA

Zacks

a year ago

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia Therapeutics stocks soar following Phase II/III win
KZIA

Clinical Trials Arena

a year ago

Kazia Therapeutics stocks soar following Phase II/III win

KZIA

MT Newswires

a year ago

Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
KZIA

PR Newswire

a year ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
KZIA

PR Newswire

a year ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Lotto 6/49 - $64 million up for grabs in the next draw!
KZIA

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
KZIA

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
KZIA

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
KZIA

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
KZIA

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
KZIA

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
KZIA

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
KZIA

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
KZIA

PR Newswire

a year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Kazia concludes first stage of Phase I advanced cancer treatment trial
KZIA

Clinical Trials Arena

a year ago

Kazia concludes first stage of Phase I advanced cancer treatment trial

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
KZIA

PR Newswire

a year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

11 Best ASX Stocks To Buy Now
KZIA

Insider Monkey

a year ago

11 Best ASX Stocks To Buy Now

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
KZIA

PR Newswire

a year ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia announces presentation of new data at AACR Annual Meeting
KZIA

PR Newswire

a year ago

Kazia announces presentation of new data at AACR Annual Meeting

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
KZIA

PR Newswire

2 years ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock
KZIA

Simply Wall St.

2 years ago

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

KZIA

GlobeNewswire

2 years ago

TRUGOLF, INC. AND DEEP MEDICINE ACQUISITION CORP. CLOSE BUSINESS COMBINATION; TRUGOLF BECOMES PUBLICLY TRADED COMPANY

Paragon Calls Out OPT’s Inaccurate Statements About Voting on the Blue Proxy Card; Vote the Blue Proxy Card and Put an End to the Corporate Greed and Drowning Share Price
KZIA

ACCESSWIRE

2 years ago

Paragon Calls Out OPT’s Inaccurate Statements About Voting on the Blue Proxy Card; Vote the Blue Proxy Card and Put an End to the Corporate Greed and Drowning Share Price

KZIA

GlobeNewswire

2 years ago

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 23, 2024

Red Cat to Participate in the 2024 SHOT Show
KZIA

GlobeNewswire

2 years ago

Red Cat to Participate in the 2024 SHOT Show

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
KZIA

PR Newswire

2 years ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

KZIA

GlobeNewswire

2 years ago

TRUGOLF, INC. AND NASDAQ-LISTED SPAC DEEP MEDICINE ACQUISITION CORP. ANNOUNCE FORM S-4 REGISTRATION STATEMENT DECLARED EFFECTIVE BY THE U.S. SECURITIES AND EXCHANGE COMMISSION AND MAILING OF DEFINITIVE PROXY STATEMENT

Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support
KZIA

PR Newswire

2 years ago

Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support

DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years
KZIA

Simply Wall St.

2 years ago

DarioHealth (NASDAQ:DRIO) shareholders are up 38% this past week, but still in the red over the last five years

MariaDB Reaches Agreement to Amend Senior Secured Promissory Note
KZIA

Business Wire

2 years ago

MariaDB Reaches Agreement to Amend Senior Secured Promissory Note

Vicinity Motor Corp. Issues DSUs
KZIA

ACCESSWIRE

2 years ago

Vicinity Motor Corp. Issues DSUs

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
KZIA

Business Wire

2 years ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Immunic, Inc. Announces Private Placement of up to $240 Million
KZIA

PR Newswire

2 years ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
KZIA

Business Wire

2 years ago

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
KZIA

GlobeNewswire

2 years ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Red Cat Endorses Passing of the American Security Drone Act
KZIA

GlobeNewswire

2 years ago

Red Cat Endorses Passing of the American Security Drone Act

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
KZIA

GlobeNewswire

2 years ago

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Millennium Group International Holdings Celebrates Prestigious Award Win at Manufacturing Asia Awards
KZIA

GlobeNewswire

2 years ago

Millennium Group International Holdings Celebrates Prestigious Award Win at Manufacturing Asia Awards

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate
KZIA

GlobeNewswire

2 years ago

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

NextCure Provides Year-End Clinical Pipeline Updates
KZIA

GlobeNewswire

2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

Aurora Mobile’s Subsidiary SendCloud Provides Email Services to Rain Classroom to Help Drive User Outreach
KZIA

GlobeNewswire

2 years ago

Aurora Mobile’s Subsidiary SendCloud Provides Email Services to Rain Classroom to Help Drive User Outreach

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
KZIA

PR Newswire

2 years ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Cumulus Media Taps Collin Jones to Lead Westwood One
KZIA

GlobeNewswire

2 years ago

Cumulus Media Taps Collin Jones to Lead Westwood One

Global Self Storage Declares Fourth Quarter 2023 Dividend
KZIA

ACCESSWIRE

2 years ago

Global Self Storage Declares Fourth Quarter 2023 Dividend

Kazia Therapeutics Announces $2 Million Registered Direct Offering
KZIA

PR Newswire

2 years ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
KZIA

PR Newswire

2 years ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
KZIA

Zacks

2 years ago

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
KZIA

GlobeNewswire

2 years ago

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

Casa Systems Sets Cable Industry Milestone with DOCSIS 4.0 Extended Spectrum Breakthrough
KZIA

GlobeNewswire

2 years ago

Casa Systems Sets Cable Industry Milestone with DOCSIS 4.0 Extended Spectrum Breakthrough

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
KZIA

PR Newswire

2 years ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
KZIA

PR Newswire

2 years ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week
KZIA

Simply Wall St.

2 years ago

Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
KZIA

PR Newswire

2 years ago

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
KZIA

GlobeNewswire

2 years ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
KZIA

PR Newswire

2 years ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KZIA

Associated Press Finance

2 years ago

Crown Crafts: Fiscal Q2 Earnings Snapshot

Crown Crafts Announces Financial Results for Second Quarter Fiscal 2024 and Declares Quarterly Dividend
KZIA

GlobeNewswire

2 years ago

Crown Crafts Announces Financial Results for Second Quarter Fiscal 2024 and Declares Quarterly Dividend

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)
KZIA

Zacks

2 years ago

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)

Downgrade: Here's How Analysts See FTC Solar, Inc. (NASDAQ:FTCI) Performing In The Near Term
KZIA

Simply Wall St.

2 years ago

Downgrade: Here's How Analysts See FTC Solar, Inc. (NASDAQ:FTCI) Performing In The Near Term

CXApp Inc. (Nasdaq:CXAI) Schedules Third Quarter 2023 Financial Results and Business Update Conference Call
KZIA

ACCESSWIRE

2 years ago

CXApp Inc. (Nasdaq:CXAI) Schedules Third Quarter 2023 Financial Results and Business Update Conference Call

American Oncology Network’s Specialty Pharmacy Reports Zero Drug Waste After Value-Based Trial, Secures Unchanged Reimbursement Rate for 2024
KZIA

GlobeNewswire

2 years ago

American Oncology Network’s Specialty Pharmacy Reports Zero Drug Waste After Value-Based Trial, Secures Unchanged Reimbursement Rate for 2024

Telesat Reports Results for the Quarter and Nine Months Ended September 30, 2023
KZIA

GlobeNewswire

2 years ago

Telesat Reports Results for the Quarter and Nine Months Ended September 30, 2023

Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Q3 2023 Earnings Call Transcript
KZIA

Insider Monkey

2 years ago

Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Q3 2023 Earnings Call Transcript

BK Technologies to Introduce InteropONE Tethering Feature Enabling Push-To-Talk-Over Broadband Capabilities for BKR 5000 and BKR 9000 Radio Customers
KZIA

ACCESSWIRE

2 years ago

BK Technologies to Introduce InteropONE Tethering Feature Enabling Push-To-Talk-Over Broadband Capabilities for BKR 5000 and BKR 9000 Radio Customers

Share on Social Networks: